Meeting
2017 Gastrointestinal Cancers Symposium
Phase I study of defactinib combined with pembrolizumab and gemcitabine in advanced cancer.
Authors
Andrea Wang-Gillam
Washington University School of Medicine in St. Louis, St. Louis, MO
Andrea Wang-Gillam , Albert C. Lockhart , Benjamin R. Tan Jr., Rama Suresh , Preet Paul Singh , Kian-Huat Lim , Katrina Pedersen , Manik A. Amin , William G. Hawkins , David G DeNardo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT02546531
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract TPS505)
DOI
10.1200/JCO.2017.35.4_suppl.TPS505
Abstract #
TPS505
Poster Bd #
O1
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer.
First Author: Andrea Wang-Gillam
Poster
2018 Gastrointestinal Cancers Symposium
Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer.
First Author: Andrea Wang-Gillam
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Updated results of a phase 1 study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC; SGNS40-001).
First Author: Andrew L. Coveler
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase 1 trial of combined MEK, STAT3 and PD-1 inhibition in metastatic pancreatic ductal adenocarcinoma (PDAC).
First Author: Peter Joel Hosein